University of Pennsylvania's School of Veterinary Medicine to Evaluate New Gastrointestinal Panel Using LexaGene's MiQLab System
BEVERLY, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic syndromic testing for veterinarians, announces the start of an evaluation of a gastrointestinal (GI) pathogen panel, in the laboratory of Stephen Cole, MS, VMD, DACVM at the University of Pennsylvania’s School of Veterinary Medicine (Penn Vet).
Dr. Jack Regan, LexaGene’s Founder and CEO stated, “GI issues such as acute diarrhea are the most common reason why companion animal owners bring their pet to see a veterinarian.1 Rapidly diagnosing GI issues caused by pathogenic bacteria, protozoans, and viruses is difficult with standard microscopy and rapid tests are either lacking or poor in sensitivity. LexaGene is excited to have started this study to prove our technology solves this pain point for veterinarians.”
Dr. Nathan Walsh, LexaGene’s VP of Applications and Bioinformatics stated, “Our GI panel screens for 5 bacteria, 11 toxins genes that are commonly associated with acute diarrhea, 4 protozoans, and a virus family that includes common GI viruses. These pathogens and toxins are commonly responsible for gastrointestial distress and knowing the identity of the pathogen and toxin genes helps guide treatment decisions.”
The MiQLab GI Pathogen Panel specifically screens for the following pathogens:
About LexaGene Holdings Inc.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues -- that could cause actual results to differ materially from the Company's expectations as disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
T 800.215.1824 | [email protected]